当前位置: X-MOL 学术Chem. Commun. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Chemical Communications ( IF 4.3 ) Pub Date : 2020-07-22 , DOI: 10.1039/d0cc03243c
Yufeng Xiao 1 , Jia Wang 2 , Lisa Y Zhao 3 , Xinyi Chen 4 , Guangrong Zheng 1 , Xuan Zhang 1 , Daiqing Liao 3
Affiliation  

Histone deacetylases (HDACs) are validated drug targets for cancer treatment. Increased HDAC isozyme selectivity and novel strategies to inhibit HDAC activity could lead to safer and more effective drug candidates. Nonetheless, it is quite challenging to develop isozyme-specific HDACi due to the highly conserved catalytic domain. We discovered XZ9002, a first-in-class HDAC3-specific PROTAC that potently degraded HDAC3. Importantly, XZ9002 is more effective to inhibit cancer cell proliferation than its proteolysis-inactive counterpart, suggesting HDAC3 degradation is a novel and promising anticancer approach.

中文翻译:


组蛋白脱乙酰酶 3 (HDAC3) 特异性 PROTAC 的发现。



组蛋白脱乙酰酶 (HDAC) 是经过验证的癌症治疗药物靶点。提高 HDAC 同工酶选择性和抑制 HDAC 活性的新策略可能会产生更安全、更有效的候选药物。尽管如此,由于高度保守的催化结构域,开发同工酶特异性 HDACi 相当具有挑战性。我们发现了 XZ9002,这是一种一流的 HDAC3 特异性 PROTAC,可有效降解 HDAC3。重要的是,XZ9002 比其无蛋白水解活性的对应物更有效地抑制癌细胞增殖,这表明 HDAC3 降解是一种新颖且有前途的抗癌方法。
更新日期:2020-08-25
down
wechat
bug